Development costs discourage pharmaceutical packaging innovation



Product development costs discourage pharmaceutical packaging innovation, says Packaging Hall of Fame inductee Edward J. Bauer in this Q&A. Bauer is senior director, product and package innovation and development for Pittsburgh-based General Nutrition Centers.

Healthcare Packaging: In the pharmaceutical sector, financial issues are more pressing today than just a few years ago. What does this mean for pharmaceutical packaging?

Edward Bauer: There are going to be fewer new developments in packaging, or at least packaging developments are going to be introduced at a slower pace. There is a limited patent life on pharmaceutical products, so the sooner you can bring that product to market, the sooner you can recover the product development costs. What it means is that manufacturers and pharmaceutical developers are reluctant to put new packaging on the critical path of a project with drug development if it might slow bringing the product to market. So they tend to rely on materials and processes of the past, or to overpackaging a product to eliminate any concern about product/package performance. This means defaulting to an existing method of packaging, or to one that maybe isn’t as elegant, but is available and [importantly] is something that regulators are familiar with.

Healthcare Packaging: Beyond R&D efforts and gaining regulatory approval, what are some of the key cost issues influencing pharmaceutical packaging?

Edward Bauer: Pharmaceutical companies are looking to their supply chain to be as efficient and as effective as possible. If you want to change a packaging material or packaging process, you have to balance the cost of development, testing, and approval with the potential cost savings. Nobody has a large staff anymore so many times it’s a question of working on a new product and getting it to market versus redesigning or refining the packaging of an existing product. There is an awful lot of tension within the companies over the competition for resources, and with the public at large, which want the lowest possible price for any product. The public wants safe and effective medications approved by the Food and Drug Administration, and companies are trying to make them for the lowest possible price. The cost of packaging development, the stability and analytical testing procedures, and the preparation and filing of an Abbreviated New Drug Application takes two or three years to accomplish to make sure that the active pharmaceutical ingredient and its packaged delivery is still efficacious. Are you going to save millions of dollars with a packaging change to help with some of these development costs, or is it better to leave the old packaging in place and focus those resources on the problems of bringing a new product to market? It’s a tough conundrum.

-–Jim Butschli, Editor-in-Chief


  1. July 2015

  2. September 2014
  3. August 2014
  4. July 2014
  5. April 2014
  6. September 2013
  7. March 2013
  8. February 2013
  9. July 2012
  10. January 2012
  11. December 2011
  12. November 2011
  13. August 2011
  14. April 2011
  15. March 2011
  16. February 2011
  17. January 2011
  18. December 2010
  19. November 2010
  20. October 2010
  21. September 2010
  22. August 2010
  23. July 2010
  24. June 2010
  25. May 2010
  26. April 2010
  27. March 2010
  28. February 2010
  29. January 2010
  30. December 2009
  31. November 2009
  32. October 2009
  33. September 2009
  34. August 2009
  35. July 2009
  36. June 2009
  37. May 2009
  38. Tag Bag

  39. Tag Cloud

  40. Twitter Feed

    Posting tweet...